Mass General Brigham launched the Hospital Integrated Research Organization (HIRO) to revolutionize sponsored research by delivering cost-effective, quality clinical trials faster. Our offerings span all medical disciplines and phases of development—from early-stage R&D to post-market analysis. HIRO accelerates clinical trials with access to world-renowned clinical experts, advanced data platforms, best-practice frameworks, and our network of Academic Medical Centers (AMCs). We enable effortless collaboration between study sites and pharmaceutical companies, offering streamlined trial execution powered by state-of-the-art data and expert knowledge.
LAT RESEARCH SRL
LAT Research is a privately held Contract Research Organization (CRO), founded in 2010 and an active member of the Argentine Chamber of Clinical Research Organizations (CAOIC). We specialize in providing regulatory-compliant, high-quality clinical research services across Latin America. We partner with global sponsors to facilitate clinical development in alignment with international regulatory standards, including those of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and ANMAT (Argentina’s National Administration of Drugs, Food and Medical Technology). ________________________________________ Clinical Trial Experience Since its establishment, our clinical operations team has supported more than 70 clinical trials across multiple phases and therapeutic areas. Our proven track record includes • Orphan and rare diseases • Translational medicine • Neglected and infectious diseases • Studies involving vulnerable or underserved populations Our operational strategies are aligned with ICH-GCP guidelines and tailored to meet both regional and global regulatory expectations. Regional Capabilities LAT Research is led by a team of senior physicians and industry experts with over 25 years of experience in clinical development and regulatory affairs. We maintain dedicated teams across Latin America, allowing for • Efficient site selection and patient recruitment • Deep understanding of local regulatory frameworks (FDA, EMA, ANMAT, INVIMA, COFEPRIS, among others) • Seamless coordination of multicenter studies Comprehensive Services for Sponsors We offer full-service CRO capabilities from early-phase trials through to registration and post-marketing studies, including: • Clinical development • Regulatory strategy and submissions • Site management and monitoring • Data management and biostatistics • Pharmacovigilance • Quality assurance and audit support Why Global Sponsors Choose LAT Research • Expertise in regulatory navigation across Latin American countries • Proven performance in complex, multicenter studies • Strong investigator networks and KOL relationships • Flexibility and client-centered project delivery • Commitment to quality, ethics, and operational excellence
Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com. Invitae is a part of Labcorp. | We are a global life sciences and healthcare company harnessing science for human good. Every day, our mission is to improve health and improve lives. | Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at https://www.labcorp.com/infectious-disease.
Kentucky Cabinet for Economic Development
Kentucky Cabinet for Economic Development creates a sustainable and active entrepreneurial ecosystem throughout the Commonwealth that is designed to identify, develop, retain and attract talented entrepreneurs utilizing an approach that focuses on inclusivity, connectivity, positivity, and a “give first” culture. KY Innovation, within the KY Cabinet for Economic Development, administers Kentucky’s SBIR/STTR Matching Funds Program. | As the primary state agency encouraging job creation, retention and business investment in Kentucky, the Cabinet for Economic Development works to attract new industries and assists existing companies to grow and expand. The Cabinet also provides support and resources for entrepreneurs, startups and small business owners. As well, it helps prepare communities for economic development opportunities. In addition to the Cabinet’s central office in Frankfort, KY, the Cabinet maintains international offices in Europe and Asia.
IZB – Innovation and Start-up Center Biotechnology
Hotspot for Life Sciences The Innovation and Start-up Center Biotechnology (IZB) with sites in Planegg-Martinsried and Freising-Weihenstephan near Munich, is one of the leading biotechnology centers in Europe. The company Fördergesellschaft IZB mbH, founded in 1995, operates IZB. IZB hosts over 40 biotech companies with more than 700 employees across a 26,000 m² area. At the main site in Planegg-Martinsried, spanning 23,000 m², resident start-ups primarily focus on medical biotechnology. IZB in Freising provides ideal conditions for founders in the life sciences sector. Outstanding infrastructure IZB offers young companies a superior environment and infrastructure for realizing their product and service ideas. Crucial for successful growth are S1 laboratories and office spaces that flexibly adapt to the companies‘ needs. Additionally, IZB provides excellent infrastructure. At the Martinsried location, start-ups have access to modern conference rooms, a design hotel, the restaurants „The Bowl“ and „Seven and More“, as well as the Bio Kids kindergarten. A strong network A vital success factor for IZB start-ups is the close proximity of both locations to cutting-edge research. On the Weihenstephan Campus, you’ll find the TUM school of Life Sciences of the Technical University of Munich, as well as the University of Applied Sciences Weihenstephan-Triesdorf. Adjacent to the IZB on the Martinsried/Großhadern campus, you‘ll find, among others, two Max Planck Institutes, faculties, and facilities of LMU, as well as the University Hospital of Munich-Großhadern. IZB fosters this strong network with an array of event formats like the IZBrunch and the Munich Life Science Pitch Day at the G2B Faculty Club, establishing itself as a key meeting point in the industry.
iRepertoire
Over the past decade, iRepertoire has developed gold standard technologies for immune repertoire sequencing. Our core technologies provide the ability to amplify expressed V(D)Js in B or T cells, and we offer the only technology that can measure all 7 immune chains simultaneously. We also offer a single cell solution to capture V(D)J rearrangements from rare cell populations. Beyond sequencing, iRepertoire now provides comprehensive data analysis services that accelerate biomarker discovery, advance disease research, and support IO drug development programs. iRepertoire is committed to creating cutting-edge technology and analytical solutions that adapt to the ever-changing immune sequencing landscape. | .
IQVIA BRASIL
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and accelerate innovations. With approximately 88,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. Learn more at www.iqvia.com.
Instant NanoBiosensors Co. Ltd
Instant NanoBiosensors (INB) is an innovative precision medicine company specializing in ultra-sensitive protein-based blood tests for Alzheimer’s disease and gene-based solutions for leukemia through its INLab NGS Solution. Revolutionizing Alzheimer’s Diagnostics Leveraging our proprietary Fiber Optic Particle Plasmon Resonance (FOPPR™) technology, we provide a non-invasive, rapid, and cost-effective solution for the early detection of Alzheimer’s-related biomarkers. Our technology enhances diagnostic accuracy, accelerates drug development, and supports personalized medicine applications for medical institutions and pharmaceutical companies. INB is the only point-of-care testing (POCT) platform on the market that enables end-to-end solutions—from antibody analysis to ultra-sensitive assay development. This platform has been adopted by the EU-funded TAuimMunE (TAME) project as a key training tool for PhD researchers. Current blood biomarker diagnostic methods are often expensive, centralized, and require specialized personnel to operate. INB’s solution addresses these limitations by making early Alzheimer’s detection more accessible and affordable. Our goal is to provide a highly accessible and precise diagnostic platform that enhances patient care and therapeutic outcomes worldwide. Leukemia Precision Medicine: INLab NGS Solution In leukemia diagnostics, INB has developed a comprehensive NGS Precision Medicine Solution that streamlines the entire workflow—from sample processing to final report generation—with fully integrated instruments, reagents, and software. We have extensive experience collaborating with National Taiwan University Hospital, working closely with hematology and oncology specialists to develop clinically relevant diagnostic reagents. Our solution currently serves nearly 70% of leukemia patients in Taiwan and has also been adopted by Yale Medical Center in the United States. Key Advantages of Our Solution ✅ Enhanced Accuracy and Efficiency: Our proprietary DimerOff™ technology minimizes primer dimer formation and sequencing noise, producing cleaner, more accurate sequencing data. This significantly improves sensitivity for detecting MDS/AML-related mutations, ensures higher clinical reliability, reduces sequencing costs by more than 50%, and shortens the turnaround time to just three days. ✅ MRD Detection & MPN Monitoring: Our solution enables precise monitoring of measurable residual disease (MRD) and myeloproliferative neoplasms (MPN), supporting long-term patient management and treatment adjustments. ✅ Customizable Panels for Specific Clinical Needs: We work closely with clinicians and researchers to develop NGS panels tailored to specific research and diagnostic requirements. Our flexible approach optimizes mutation detection, enhances patient stratification, and reduces operational costs for both research and clinical applications. Through continuous innovation and strategic partnerships, INB is committed to transforming precision medicine and improving patient outcomes worldwide. We Are Seeking Partnerships With: International Distributors interested in bringing our innovative diagnostic solutions to global markets. Biotech Companies looking for co-development opportunities in assay and panel development. Pharmaceutical Companies seeking companion diagnostics solutions to support targeted drug development. Hospitals & CROs aiming to establish a comprehensive precision medicine system within their organization. Scientists & Research Institutions interested in collaborative grant applications. If you are interested in collaborating with us, we welcome the opportunity to discuss how INB’s cutting-edge solutions can support your research, clinical, and commercial objectives.
Inscinstech Co.,Ltd.
Inscinstech Co., Ltd. is an innovative high-tech enterprise focusing on biological separation technology. It has a large number of patents and computer software copyrights. The company has established marketing and service centers in Suzhou, China. It is committed to providing global customers with high-quality biological separation equipment and chemical analysis instruments, reducing customer operating costs and creating value for customers. The company has established R & D centers , which run by an international level technical R & D team with a perfect product R & D system. The technical team of the company has more than ten years of R & D, engineering and industrialization experience in the fields of laboratory sample pretreatment, chromatography, spectrum and mass spectrometry analysis instruments, automation equipment and machine vision technology, and provides customers with all-round intelligent solutions from sample separation, pretreatment to laboratory chemical analysis.